Yeah, the current limitation of MRI biomarkers is the delay in detecting neurodegenerative diseases, especially in PET imaging early can detect amyloid and tau pathology for Alzheimer’s disease. In contrast, neurodegeneration on MRI is just a little bit delayed compared to amyloid and tau imaging biomarkers. That’s the most significant limitation for MRI biomarkers for Alzheimer’s disease and Parkinson’s disease...
Yeah, the current limitation of MRI biomarkers is the delay in detecting neurodegenerative diseases, especially in PET imaging early can detect amyloid and tau pathology for Alzheimer’s disease. In contrast, neurodegeneration on MRI is just a little bit delayed compared to amyloid and tau imaging biomarkers. That’s the most significant limitation for MRI biomarkers for Alzheimer’s disease and Parkinson’s disease. To overcome the issues of the limitation for MRI, we detect perforant path fibers for neurodegeneration. These biomarkers are the earliest detectable neurodegenerative change point for Alzheimer’s and Parkinson’s disease. That’s why we focus on the perforant path fibers neurodegenerative changes. The key finding of this perforant path fiber count is the number of perforant path fibers decreasing along the Alzheimer’s pathology. In contrast, the area and density of the perforant path fiber counts are not decreasing. So the number of perforant path fibers is the most important parameter of neurodegeneration. What we did is to visualize using ex vivo neuroimaging. So we have to translate from ex vivo to in vivo. So we focus on the clinical research using in vivo human MRI brain research.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
